Michael Severino - 28 Jul 2026 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: SRPT
Reported as of: 28 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jul 2026, 20:05:03 UTC
Prior SEC filing: 11 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Michael Severino

Key filing fact

Michael Severino filed Form 4 for Sarepta Therapeutics, Inc. (SRPT) on 29 Jul 2026.

Key facts

This page summarizes Michael Severino's Form 4 filing for Sarepta Therapeutics, Inc. (SRPT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Jul 2026, 20:05.

Change

Previous filing in this sequence was filed on 11 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001609447 Primary reporting owner

SEVERINO MICHAEL

Relationship: Chief Executive Officer, Director
Address: 215 FIRST STREET
Signature: /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Michael Severino
Signature date: 29 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SRPT transaction

Common Stock

Award

Transaction value
Shares: +756,104
Change %
Price
Shares after: 756,104
Date: 28 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SRPT transaction Derivative

Stock Options (right to buy)

Award

Transaction value
Shares: +2,224,342
Change %
Price: $0.000000^*
Shares after: 2,224,342
Date: 28 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,224,342
Exercise price: $17.74
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment.

Footnote F2

Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment.